Search

Your search keyword '"alpha-Galactosidase therapeutic use"' showing total 660 results

Search Constraints

Start Over You searched for: Descriptor "alpha-Galactosidase therapeutic use" Remove constraint Descriptor: "alpha-Galactosidase therapeutic use"
660 results on '"alpha-Galactosidase therapeutic use"'

Search Results

251. Fabry disease with atypical neurological presentation: report of a case.

252. [Court-ordered access to treatment of rare genetic diseases: Fabry Disease in the state of Rio Grande do Sul, Brazil].

253. Agalsidase alfa: a review of its use in the management of Fabry disease.

254. Enzyme replacement therapy improves cardiac features and severity of Fabry disease.

255. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).

256. [Fabry disease : diagnosis and treatment].

257. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).

258. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.

259. A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency.

261. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey.

262. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature.

263. Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice.

264. Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.

265. Fabry disease, enzyme replacement therapy and the significance of antibody responses.

266. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.

267. Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneys.

268. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.

269. Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy.

270. Avascular necrosis of bilateral femoral heads in a patient with Fabry's disease.

271. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.

272. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.

273. Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.

274. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.

275. Metronomic breathing shows altered parasympathetic baroreflex function in untreated Fabry patients and baroreflex improvement after enzyme replacement therapy.

276. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.

277. Petechial-like lesions, eye abnormalities, and albuminuria in a young boy.

278. Confocal laser-scanning microscopy allows differentiation between Fabry disease and amiodarone-induced keratopathy.

279. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.

280. Young woman with recurrent ischemic strokes diagnosed as Fabry disease: lessons learned from a case report.

281. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.

282. pH-responsive polysaccharide-based polyelectrolyte complexes as nanocarriers for lysosomal delivery of therapeutic proteins.

283. [Consensus for the study and treatment of Fabry disease. GETER Foundation].

284. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey.

285. Modelling the resource implications of managing adults with Fabry disease in Italy.

286. [Fabry-Anderson disease: current state of knowledge].

287. A united front.

288. Safety of agalsidase alfa in patients with Fabry disease under 7 years.

289. Update on role of agalsidase alfa in management of Fabry disease.

290. Fabry disease in an oligosymptomatic male.

291. Thyroid function in Fabry disease before and after enzyme replacement therapy.

292. Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A.

293. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

294. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.

295. [Neurological complications of Fabry-disease].

296. ACE activity is modulated by the enzyme α-galactosidase A.

297. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.

298. Letter regarding Brouns et Al, Baptista et Al, and Wozniak et Al.

299. A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy.

300. The heart in Fabry's disease.

Catalog

Books, media, physical & digital resources